KANGSTEM BIOTECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,635 KRW | -1.50% |
|
-0.94% | +10.02% |
| Sales 2022 | 16.3B 11.93M | Sales 2023 | 12.7B 9.3M | Capitalization | 134B 98.07M |
|---|---|---|---|---|---|
| Net income 2022 | -20.24B -14.81M | Net income 2023 | -21.95B -16.07M | EV / Sales 2022 | 5.31 x |
| Net cash position 2022 | 23.31B 17.06M | Net cash position 2023 | 23.75B 17.39M | EV / Sales 2023 | 8.68 x |
| P/E ratio 2022 |
-5.43
x | P/E ratio 2023 |
-4.43
x | Employees | 115 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.7% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.50% | ||
| 1 week | -0.94% | ||
| Current month | +40.61% | ||
| 1 month | +40.61% | ||
| 3 months | +32.48% | ||
| 6 months | +96.20% | ||
| Current year | +10.02% |
1 week
2 600.00
3 110.00
1 month
1 860.003 110.00
Current year
1 713.003 110.00
1 year
1 166.003 485.00
3 years
1 166.007 150.00
5 years
1 166.0021 450.00
10 years
1 166.0024 400.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jong-Chun Na
CEO | Chief Executive Officer | 61 | - |
Seung-Hee Lee
CTO | Chief Tech/Sci/R&D Officer | 43 | - |
Seung-Won Im
AUD | Comptroller/Controller/Auditor | 64 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yong-Ho Park
BRD | Director/Board Member | 68 | - |
Jung-Ho Choi
BRD | Director/Board Member | 63 | - |
Sang-Kyun Lee
BRD | Director/Board Member | 71 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 2,555 | -3.04% | 432,483 |
| 24-04-30 | 2,635 | -1.50% | 572,005 |
| 24-04-29 | 2,675 | -.--% | 549,955 |
| 24-04-26 | 2,675 | -10.08% | 1,430,535 |
| 24-04-25 | 2,975 | +4.39% | 2,566,780 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
Kang Stem Biotech Co., LTD is a Korea-based company mainly engaged in the development of pharmaceutical products. The Company's product portfolio consists of stem cell therapy products including Furestem-AD which used for treating atopic dermatitis, Furestem-RA which used for treating rheumatoid arthritis, Furestem-CD which used for treating crohnâs disease, stem cell conditioned medias which used as raw materials of cosmetics including umbilical cord blood-derived stem cell conditioned medias (USC-CMs) and others and stem cell culture medias including KSB-3 Complete Kit and others. The Company distributes its products within domestic market and to overseas markets.
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +10.02% | 107M | |
| +27.01% | 42.68B | |
| -3.48% | 42.4B | |
| +45.32% | 40.04B | |
| -6.20% | 28.31B | |
| +6.61% | 24.94B | |
| -21.44% | 18.96B | |
| +28.03% | 12.3B | |
| -2.76% | 11.95B | |
| -1.80% | 11.55B |
- Stock Market
- Equities
- A217730 Stock
